First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

Inclusion Criteria:

• Healthy adults aged ≥18 years and ≤ 45 years of age on the day of the screeningvisit

• Completed the written informed consent process

• Confirmed HIV-negative at screening

• Confirmed Xpert MTB/RIF Ultra-negative at screening

• Laboratory values within the indicated ranges obtained at screening:

• Absolute neutrophil count (ANC) ≥800 cells/mm3

• Haemoglobin ≥ 11 g/dL for females and >10.5 g/dL for males

• Platelet count ≥ 100,000/mm3

• Serum creatinine ≤ 1.5 X upper limit of normal (ULN)

• AST (SGOT), ALT (SGPT), and alkaline phosphatase, ≤ 2.5 X ULN

• Total bilirubin ≤ 2 X ULN)

• Agrees to refrain from blood donation during the course of the trial

• Women of child-bearing potential must use a highly effective form of birth control (confirmed by the investigator) throughout the trial

• A highly effective method of birth control is defined as hormonalcontraceptives (oral, injection, transdermal patch, or implant), bilateraltubal occlusion or intrauterine device. The participants must have used thecontraceptive method continuously for at least 21 days prior to the pregnancytest at baseline (Day 1)

• A female is defined as not being of child-bearing potential if she ispostmenopausal (aged 50 and above with at least 12 months with no menseswithout an alternative medical cause prior to screening. If less than 50 yearsold, then confirmatory Follicular stimulating hormone testing is required)

• A female is defined as not being of child-bearing potential if she issurgically sterile (hysterectomy, bilateral salpingectomy, or bilateraloophorectomy). Written evidence of surgical sterility would be optimal

• Agrees to give access to medical records for trial related purposes

• Agrees to stay in contact with the trial site for the duration of the trial, provideupdated contact information as necessary and has no current plans to move from thearea for the duration of the trial

Exclusion Criteria:

• Previous diagnosis or current diagnosis of TB, including suspected subclinical TB

• Reported current household contact with TB. Note: Daily caregivers to TB infectedpersons will be considered as household contacts

• History of or ongoing severe disease that in the opinion of the investigator mightaffect the safety of the participant or the immunogenicity of the trial product

• Insulin-dependent diabetes

• History of allergic disease or reactions likely to be exacerbated by any componentof the trial product

• History of chronic allergic rhinitis likely to interfere with the assessment of themucosal recall

• History of frequent or severe epistaxis

• History or laboratory evidence of primary and/or acquired immunodeficiency,autoimmune disease, or immunosuppression

• History of a malignant condition (e.g. lymphoma, leukaemia, Hodgkin's disease orother tumours of the reticuloendothelial system)

• History of chronic hepatitis

• Has a body mass index ≤18 or ≥35 at screening (weight [kg] / (height [m] * height [m]))

• Abnormal chest X-ray at screening

• Receipt or planned receipt of any other investigational TB vaccine

• Receipt or planned receipt of any other investigational drug

• Receipt of emergency use authorised/emergency use listed [EUA/EUL] vaccines orlicensed live attenuated vaccines (e.g., measles, mumps, and rubella [MMR], oralpolio vaccine [OPV], varicella, yellow fever, live attenuated influenza vaccine,live attenuated COVID-19 vaccine) within 30 days prior to screening

• Receipt of any EUA/EUL or licensed vaccines that are not live attenuated vaccines (e.g., tetanus, pneumococcal, Hepatitis A or B, not live attenuated COVID-19vaccine) within 14 days prior to screening

• Receipt of anticoagulant therapy, including daily acetylsalicylic acid product.NOTE: Intermittent symptomatic use is permitted

• Receipt of treatment likely to modify the immune response (e.g. blood products,immunoglobulins) within 42 days before screening

• Receipt of immunosuppressive medications, including radiotherapy, nasalcorticosteroids and inhaled corticosteroids. NOTE: Use of the following ispermitted:

• Topical corticosteroids for mild, uncomplicated dermatologic conditions exceptif administered on the site of injection of trial products

• A single course of oral/parenteral prednisone or equivalent at doses <60 mg/dayand for <11 days with completion at least 30 days prior to screening

• Female participants: if lactating/nursing, or pregnant as per positive pregnancytest

• Not suitable for inclusion in the opinion of the investigator